Seastar Medical Holding Corp (ICU) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Seastar Medical is a commercial-stage healthcare company developing Selective Cytopheretic Devices (SCDs) to treat hyperinflammation. The company received FDA approval under a Humanitarian Device Exemption (HDE) for its pediatric therapy, QUELIMMUNE, in February 2024 and began commercial shipments in July 2024. It is currently conducting a pivotal clinical trial for its adult SCD therapy.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenue | $293,000 | $0 |
| Net Loss | $(3,772,000) | $(12,697,000) |
| Operating Loss | $(3,822,000) | $(3,950,000) |
| Cash and Equivalents (End of Period) | $5,296,000 | $5,019,000 |
| Net Cash Used in Operating Activities | $(2,654,000) | $(3,488,000) |
| Net Cash Provided by Financing Activities | $6,131,000 | $8,331,000 |
| Total Assets | $7,597,000 | $4,658,000 |
| Total Liabilities | $7,032,000 | $6,841,000 |
| Stockholders' Equity | $565,000 | $(2,183,000) |
Note: All figures in thousands except per-share data. The company reported a net loss per share of $(0.44) for Q1 2025.
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $293,000 in revenue from QUELIMMUNE sales, compared to zero in Q1 2024, following the commencement of commercial operations in July 2024.
- Significant Reduction in Net Loss: Net loss decreased by approximately 70% (from $12.7M to $3.8M). This improvement was primarily driven by the absence of non-operating losses related to the fair value adjustments of convertible notes and liability-classified warrants, which totaled $8.6M in losses in Q1 2024.
- Operating Expenses: Total operating expenses increased slightly by 4% to $4.1M. Research and Development (R&D) expenses rose 43% to $2.4M due to the expansion of the NEUTRALIZE-AKI pivotal trial (from 5 to 16 sites). General and Administrative (G&A) expenses decreased 25% to $1.7M, largely due to the absence of restatement-related accounting costs incurred in the prior year.
- Liquidity Position: Cash balances increased from $1.8M at year-end 2024 to $5.3M at March 31, 2025, fueled by a $6.0M registered direct offering in February 2025 and proceeds from pre-funded warrants.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that cash on hand ($5.3M) is insufficient to fund operations for the next 12 months. The filing raises "substantial doubt" about the company's ability to continue as a going concern without additional capital.
- Capital Raising: The company is actively seeking additional funding through equity or debt. In a subsequent event (April 2025), the company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, committing to purchase up to $15.0 million of common stock.
- Legal Proceedings: The company is defending a putative securities class action lawsuit filed in July 2024 alleging misstatements regarding financial restatements. No liability has been accrued as the outcome is not probable or estimable.
- Commercialization: The company has five customer sites for QUELIMMUNE as of March 31, 2025. Future revenue depends on the successful rollout of the pediatric device and the regulatory approval of the adult SCD.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.3M cash balance against the stated burn rate and the timeline for the next financing round.
- Lincoln Park Agreement: Review the terms of the $15M equity line of credit entered into in April 2025, specifically the pricing mechanism (97% of lowest sale price) and potential dilution.
- Class Action Status: Monitor the progress of the Wells v. SeaStar Medical class action lawsuit regarding financial restatements.
- Clinical Trial Progress: Track enrollment and data readouts for the NEUTRALIZE-AKI pivotal trial, which is driving the increase in R&D spend.
- Warrant Exercise: Assess the likelihood of warrant exercises given the current stock price is significantly below the exercise prices of many outstanding tranches (e.g., $287.50 for legacy warrants).